Sugi Predict

Sugi Predict / Compounds / SCHEMBL356822

SCHEMBL356822

SCHEMBL356822

CN(C)C(=O)c1ccc(N)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.42
▸ PIK3CA P42336 2/20 0.41
▸ MTOR P42345 2/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ MET P08581 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CES2 O00748 1/20 0.38
▸ CES1 P23141 1/20 0.38
▸ TDP1 Q9NUW8 3/20 0.38
▸ POLB P06746 2/20 0.38
▸ DGAT1 O75907 1/20 0.38
▸ AR P10275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5906549 0.85 AR (0.47) KMT2APIK3CAMTORALDH1A1MAPT
SCHEMBL2645212 0.83 PIK3CA (0.45) PIK3CAMTORALDH1A1MAPTKDM4E
SCHEMBL642910 0.81 CES2 (0.61) KMT2AL3MBTL1CES2CES1
SCHEMBL13666711 0.81 ALOX5AP (0.43) ALDH1A1SMN1; SMN2TDP1BLMHPGD
SCHEMBL2577265 0.79 PDE10A (0.45) KMT2AALDH1A1MAPTKDM4EGAA
SCHEMBL355779 0.79 PDK2 (0.47) KMT2AALDH1A1MAPTCYP3A4SMN1; SMN2
SCHEMBL2735675 0.79 PDK2 (0.46) KMT2APIK3CAMTORALDH1A1SMN1; SMN2
SCHEMBL24722194 0.79 MEN1 (0.42) KMT2AALDH1A1MAPTKDM4EGAA
SCHEMBL8280039 0.79 MAOB (0.45) KMT2AALDH1A1MAPTKDM4EGAA
SCHEMBL30476086 0.79 MAOB (0.45) KMT2AALDH1A1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116262736-B Novel oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2025-05-13 — — CN disclosed
CN-116283750-B Heterocyclic amide derivative and preparation method and application thereof 成都泰和伟业生物科技有限公司 2025-02-07 — — CN disclosed
CN-116283750-A Heterocyclic amide derivative and preparation method and application thereof 成都泰和伟业生物科技有限公司 2023-06-23 — — CN disclosed
CN-116262736-A Novel oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2023-06-16 — — CN disclosed
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-16 — — US disclosed
EP-2792674-B1 IMIDAZOLIDINEDIONE COMPOUNDS AND THEIR USES HINOVA PHARMACEUTICAL INC (CN) 2016-05-25 — — EP disclosed
US-9346764-B2 Imidazolidinedione compounds and their uses HINOVA PHARMACEUTICALS INC. (CN) 2016-05-24 — — US disclosed
US-9346764-B2 Imidazolidinedione compounds and their uses HINOVA PHARMACEUTICALS INC. (CN) 2016-05-24 — — US disclosed
US-9346764-B2 Imidazolidinedione compounds and their uses HINOVA PHARMACEUTICALS INC. (CN) 2016-05-24 — — US disclosed
US-9115092-B2 Substituted quinazoline and pyrido-pyrimidine derivatives ASANA BIOSCIENCES, LLC (US) 2015-08-25 — — US disclosed
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 — — US disclosed
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 — — US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 — — EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 — — US disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 — — US disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 — — US disclosed
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 — — US disclosed
WO-2009112565-A1 THIAZOLYL-DIHYDRO-INDAZOLES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 KMT2A 2953/4885PIK3CA 1721/4885MTOR 3118/4885
US-20230051589-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 KMT2A 4465/4885PIK3CA 3199/4885MTOR 749/4885
US-20120108567-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R KMT2A 2863/4885PIK3CA 2993/4885MTOR 282/4885
US-20110118208-A1 Thiazolyl-Dihydro-Indazoles MKI67, CYP11B1, IGF1R KMT2A 2863/4885PIK3CA 2993/4885MTOR 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.